Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Goethe University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04230759CT.gov Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group | — | Active Not Recruiting | — | — | — |
NCT03439085CT.gov DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Goethe University | P2 | CCC · 51 |
| Fluorouracilum | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Carboplatin | Dustin Deming | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P3 | BB |
| Muamycin | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Cyclophosphamide | Christian Hinrichs | P2 | BB |
| Oxaliplatin | University of Cincinnati | P2/3 | B |
+42 more in the Anal Carcinoma cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Anal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-anal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →